CR20200202A - Metodos de uso y composiciones que contienen dulaglutida - Google Patents

Metodos de uso y composiciones que contienen dulaglutida

Info

Publication number
CR20200202A
CR20200202A CR20200202A CR20200202A CR20200202A CR 20200202 A CR20200202 A CR 20200202A CR 20200202 A CR20200202 A CR 20200202A CR 20200202 A CR20200202 A CR 20200202A CR 20200202 A CR20200202 A CR 20200202A
Authority
CR
Costa Rica
Prior art keywords
methods
compositions containing
dulaglutide
containing dulaglutide
doses
Prior art date
Application number
CR20200202A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Gordon Werner
David Andrew Cox
Zvonko Milicevic
David Bradley Woodward
Lai San Tham
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20200202(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20200202A publication Critical patent/CR20200202A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
CR20200202A 2017-11-21 2018-11-13 Metodos de uso y composiciones que contienen dulaglutida CR20200202A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589244P 2017-11-21 2017-11-21
PCT/US2018/060716 WO2019103875A2 (en) 2017-11-21 2018-11-13 Methods of using and compositions containing dulaglutide

Publications (1)

Publication Number Publication Date
CR20200202A true CR20200202A (es) 2020-08-20

Family

ID=64572530

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200202A CR20200202A (es) 2017-11-21 2018-11-13 Metodos de uso y composiciones que contienen dulaglutida

Country Status (21)

Country Link
US (2) US11576950B2 (https=)
EP (1) EP3713593A2 (https=)
JP (3) JP7221956B2 (https=)
KR (2) KR20220146656A (https=)
CN (2) CN120478602A (https=)
AU (2) AU2018372709B2 (https=)
BR (1) BR112020007817A2 (https=)
CL (1) CL2020001252A1 (https=)
CR (1) CR20200202A (https=)
DO (1) DOP2020000104A (https=)
EA (1) EA202090971A1 (https=)
EC (1) ECSP20026436A (https=)
IL (1) IL274563B2 (https=)
JO (1) JOP20200126B1 (https=)
MA (1) MA50798A (https=)
MX (1) MX2020005231A (https=)
PE (1) PE20200847A1 (https=)
PH (1) PH12020550795A1 (https=)
SG (1) SG11202003687RA (https=)
UA (1) UA127588C2 (https=)
WO (1) WO2019103875A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020190591A1 (en) * 2019-03-15 2020-09-24 Eli Lilly And Company Preserved formulations
MX2022009383A (es) * 2020-01-30 2022-11-07 Lilly Co Eli Usos terapéuticos de dulaglutida.
JP2023525898A (ja) * 2020-05-19 2023-06-19 エフ． ホフマン－ラ ロシュ アーゲー 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用
CN117915939A (zh) 2021-06-23 2024-04-19 伊莱利利公司 肠降血糖素类似物用于血糖控制和体重管理

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
EA011166B1 (ru) 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1
CN101730523A (zh) * 2007-07-10 2010-06-09 伊莱利利公司 GLP-1-Fc融合蛋白质制剂
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
JP7191043B2 (ja) 2017-06-01 2022-12-16 イーライ リリー アンド カンパニー 慢性腎疾患の治療のためのデュラグルチド

Also Published As

Publication number Publication date
EP3713593A2 (en) 2020-09-30
UA127588C2 (uk) 2023-10-25
JOP20200126A1 (ar) 2020-05-21
JP7818412B2 (ja) 2026-02-20
US11576950B2 (en) 2023-02-14
KR20220146656A (ko) 2022-11-01
IL274563A (en) 2020-06-30
CL2020001252A1 (es) 2020-10-30
IL274563B1 (en) 2023-08-01
AU2022203372A1 (en) 2022-06-09
SG11202003687RA (en) 2020-06-29
CN111356472A (zh) 2020-06-30
JP7221956B2 (ja) 2023-02-14
ECSP20026436A (es) 2020-06-30
MX2020005231A (es) 2020-08-24
PH12020550795A1 (en) 2021-04-19
IL274563B2 (en) 2023-12-01
KR102589234B1 (ko) 2023-10-16
AU2022203372B2 (en) 2025-04-10
NZ763815A (en) 2023-11-24
US20240189394A1 (en) 2024-06-13
MA50798A (fr) 2020-09-30
JP2024056908A (ja) 2024-04-23
AU2018372709A1 (en) 2020-05-14
CN120478602A (zh) 2025-08-15
BR112020007817A2 (pt) 2020-10-06
JP2021502379A (ja) 2021-01-28
WO2019103875A3 (en) 2019-07-25
US20200330558A1 (en) 2020-10-22
JP2022062153A (ja) 2022-04-19
WO2019103875A2 (en) 2019-05-31
EA202090971A1 (ru) 2020-08-07
DOP2020000104A (es) 2020-08-31
CA3082625A1 (en) 2019-05-31
AU2018372709B2 (en) 2022-04-28
KR20200076705A (ko) 2020-06-29
PE20200847A1 (es) 2020-08-18
JOP20200126B1 (ar) 2024-04-18

Similar Documents

Publication Publication Date Title
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
PH12018500950B1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
PH12020550703A1 (en) Sulfonamide compounds and use thereof
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
TW201613880A (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
MX2017004617A (es) Variantes estabilizadas de alfa amilasa y su uso.
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
JOP20200126A1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
PH12019502469B1 (en) Novel fragrance compositions and products with mood enhancing effects
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2018012797A (es) Inhibidores de erbb y usos de los mismos.
MX2020002793A (es) Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados.
MX2020003763A (es) Composiciones de flumioxazina y metodos para usar las mismas.
PH12017501897A1 (en) 2-thiopyrimidinones
MX383947B (es) Composiciones de colágeno 7 y métodos para usar las mismas.